[
  {
    "ts": null,
    "headline": "Incyte Corp. stock outperforms competitors despite losses on the day",
    "summary": "Incyte Corp. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=120fa84f7e3b401cbb555cfc7820274fff99b8c75883e70d8cbee9b3cf0ec314",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743009420,
      "headline": "Incyte Corp. stock outperforms competitors despite losses on the day",
      "id": 133655060,
      "image": "",
      "related": "INCY",
      "source": "MarketWatch",
      "summary": "Incyte Corp. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=120fa84f7e3b401cbb555cfc7820274fff99b8c75883e70d8cbee9b3cf0ec314"
    }
  },
  {
    "ts": null,
    "headline": "Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico",
    "summary": "MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (\"Knight\"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. Minjuvi® in combination with lenalidomide, followed by Minjuvi® monotherapy, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are not eligible for autolo",
    "url": "https://finnhub.io/api/news?id=ffe4e9cb2148d97d11287a573a3f390bf43b8b59588332be06ad051931d3ba56",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742988600,
      "headline": "Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico",
      "id": 133448884,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (\"Knight\"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. Minjuvi® in combination with lenalidomide, followed by Minjuvi® monotherapy, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are not eligible for autolo",
      "url": "https://finnhub.io/api/news?id=ffe4e9cb2148d97d11287a573a3f390bf43b8b59588332be06ad051931d3ba56"
    }
  }
]